Hafslund Nycomed (Norway) moves into nuclear medicine
This article was originally published in Clinica
Executive Summary
Hafslund Nycomed (Norway) has added a new dimension to its Imaging Division through an investment in Diatech's (US) nuclear medicine imaging agents. The development and marketing agreement gives Nycomed a five-year option to an exclusive licence for Europe and the Middle East as well as an exclusive co-promotion agreement for the agents in the US. In return, Hafslund Nycomed will make a $10 million equity investment in Diatech and provide R&D support. Diatech will also receive additional payments and royalties.
You may also be interested in...
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.